MMRV is an acronym related to following viruses:
Measles, a highly contagious virus, transmitted in droplets through coughing and sneezing. Complications include encephalitis, which occurs in 1 per 1,000 cases of natural measles, and will frequently result in permanent brain damage or death. Pneumonia affects approximately 5% of children with measles, which occurs in 1 to 3 of every 1,000 children within the United States.
Mumps, a virus spread from person to person by secretions sneezed or coughed from the nose or throat. Complications can include inflamed testicles (20% to 50% of post-pubertal males infected), brain involvement including aseptic meningitis (15% of cases) and inflammation of the pancreas and ovaries.
Rubella, a virus transmitted through mucus droplets in the environment. Rubella in pregnancy can lead to congenital rubella syndrome (CRS) in the fetus. This is characterized by deafness, mental retardation, and heart defects. Up to 85% of expectant mothers infected in the first trimester are at risk of miscarriage or a baby with CRS.
Varicella-zoster, a virus spread through direct contact with fluid from the rash blisters. Chickenpox can cause pneumonia (23 in 10,000 cases) and is a risk factor for developing severe invasive group A streptococcal disease. Complications of varicella include bacterial infections (up to 5% of cases), decreased platelets, arthritis, hepatitis, and brain inflammation (1 in 10,000 cases). If contracted in early pregnancy, VZV can cause abnormalities in 2% of cases.
The MMRV panel consists of Measles, Mumps, Rubella, and VZV assays with characteristics to ensure superior performance and simple result interpretation. The assays related to the viruses are able to detect IgG antibodies.
The MMRV vaccine, a combined vaccine against measles, mumps, rubella and varicella, has been proposed as a replacement for the MMR vaccine to simplify administration of the vaccines.
DiaSorin offers a complete MMRV panel, on the LIAISON® systems.